washington semaglutide & tirzepatide A recent, large-scale observational study published in The BMJ by researchers semaglutide & tirzepatide washington is

Ideal candidates typically include adults with type 2 diabetes who have inadequate glycaemic control (HbA1c above individualised target) despite treatment with metformin and/or other oral agents, particularly those with additional cardiovascular or renal risk factors

Neither form is FDA approved

To qualify for Ozempic, you need to have a diagnosis of type 2 diabetes

(PubMed) Iwase S, Kawaguchi T, Yotsumoto D, et al

Europe Sees Substantial Growth Backed by Strong Healthcare Systems and Reimbursement Policies The Europe GLP-1 receptor agonist market is projected to witness substantial growth during the forecast period due to strong healthcare systems, widespread clinical acceptance of GLP-1 therapies, and rising focus on integrating diabetes devices and obesity management